Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy

MicroRNAs (miRNAs), which are endogenous about 20-23 nucleotides non-coding RNAs, have been acted as post-transcriptional regulators of gene expression. Current studies demonstrated that miRNAs are promising candidates for tumor gene therapy because of their important biological functions in tumor c...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international 2018-07, Vol.18 (1), p.101-101, Article 101
Main Authors: Wang, Hairong, Liu, Shiming, Jia, Li, Chu, Fengyun, Zhou, Ya, He, Zhixu, Guo, Mengmeng, Chen, Chao, Xu, Lin
Format: Article
Language:English
Subjects:
Apoptosis
Cancer therapies
Cell adhesion & migration
Cell growth
Cell proliferation
Drug resistance
Efficiency
Gene expression
Gene therapy
Growth factors
Immunogenicity
Kinases
Lipids
Liver cancer
Lung cancer
Metastases
Metastasis
MicroRNA
MicroRNAs
miRNA
Nanoparticles
Nanostructured lipid carrier (NLC)
Nucleotides
Pancreatic cancer
Post-transcription
Regulators
Review
Toxicity
Tumor
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MicroRNAs (miRNAs), which are endogenous about 20-23 nucleotides non-coding RNAs, have been acted as post-transcriptional regulators of gene expression. Current studies demonstrated that miRNAs are promising candidates for tumor gene therapy because of their important biological functions in tumor cell proliferation, metastasis, apoptosis, and drug resistance. As an important delivery system, nanostructured lipid carriers (NLCs) have great potential in tumor gene therapy, particularly for miRNA delivery, due to low toxicity, low immunogenicity, long metabolic cycles, and easy modification. This article reviews recent research progress on NLCs for miRNA delivery in tumor gene therapy and prospective applications.
ISSN:1475-2867
1475-2867
DOI:10.1186/s12935-018-0596-x